Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials

• Main Authors: Bianca M. Piraccini (Author), Manabu Ohyama (Author), Brittany Craiglow (Author), Anthony Bewley (Author), Yuxin Ding (Author), Yun‐Fei Chen (Author), Yves Dutronc (Author), Evangeline Pierce (Author), Frederick Durand (Author), Arash Mostaghimi (Author)
• Format: Book
• Published: Wiley, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Alopecia areata (AA) is an autoimmune hair loss disorder associated with high rates of emotional and psychosocial distress. Baricitinib, an oral selective Janus kinase (JAK) 1 and JAK 2 inhibitor, was superior to placebo with respect to hair regrowth in two phase 3 trials involvi...